Rite Aid Corporation
RADCQ · Other OTC · USD
0,01USD
+0,0079 (+376,19 %)Stand 3. Sept., 20:00
Kennzahlen
- Eröffnung
- 0,0021
- Vortag
- 0,0021
- Tagesspanne
- 0,0021 – 0,01
- 52 Wochen
- 0,0001 – 0,9599
- Volumen
- 342
- Ø Volumen
- 33.601
- Börsenwert
- 559.740 $
- KGV
- -0,0
- Gewinn je Aktie (TTM)
- -29,43
- Dividendenrendite
- 0,0 %
- Beta
- 1,3
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 24,09 Mrd. | 24,57 Mrd. | 24,04 Mrd. | 21,93 Mrd. | 21,64 Mrd. |
| Herstellungskosten | 19,29 Mrd. | 19,46 Mrd. | 19,58 Mrd. | 17,46 Mrd. | 16,96 Mrd. |
| Bruttogewinn | 4,8 Mrd. | 5,11 Mrd. | 4,46 Mrd. | 4,47 Mrd. | 4,68 Mrd. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 4,74 Mrd. | 4,94 Mrd. | 4,33 Mrd. | 4,22 Mrd. | 4,59 Mrd. |
| Operatives Ergebnis | 64,36 Mio. | 170,75 Mio. | 131,69 Mio. | 245,06 Mio. | 83,98 Mio. |
| EBITDA | 340,94 Mio. | 466,44 Mio. | 408,29 Mio. | 476,32 Mio. | −3,87 Mio. |
| Nettogewinn | −719,19 Mio. | −522,37 Mio. | −90,91 Mio. | −452,17 Mio. | −796,83 Mio. |
| Gewinn je Aktie (verwässert) | -13,15 | -9,66 | -1,69 | -8,50 | -15,08 |
Bewertung
Letzte 12 Monate
- KGV
- -0,0
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- -0,0
- PEG
- 0,0
- Bruttomarge
- 19,9 %
- Operative Marge
- 0,3 %
- Nettomarge
- −3,0 %
- Verschuldungsgrad
- -9,8
- EV/EBITDA
- 16,6
- Eigenkapitalrendite
- 300,7 %
- Kapitalrendite (ROIC)
- 1,0 %
- Free-Cashflow-Rendite
- −53.618,5 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 19,9 % | 20,8 % | 18,6 % | 20,4 % | 21,6 % |
| Operative Marge | 0,3 % | 0,7 % | 0,5 % | 1,1 % | 0,4 % |
| Nettomarge | −3,0 % | −2,1 % | −0,4 % | −2,1 % | −3,7 % |
| KGV | -0,0 | -0,0 | -0,6 | -0,1 | -0,0 |
| Kurs-Umsatz-Verhältnis | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Kurs-Buchwert-Verhältnis | -0,0 | 0,2 | 0,1 | 0,1 | 0,0 |
| Verschuldungsgrad | -9,8 | 51,2 | 10,5 | 9,3 | 2,9 |
| Liquidität 3. Grades | 1,2 | 1,2 | 1,4 | 1,3 | 1,7 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 5,67 Mrd. | 5,91 Mrd. | 6,33 Mrd. | 6,12 Mrd. | 3,39 Mrd. |
| EV/EBITDA | 16,6 | 12,7 | 15,5 | 12,9 | -876,5 |
| Eigenkapitalrendite | 121,0 % | −451,0 % | −14,8 % | −67,0 % | −67,1 % |
| Kapitalrendite (ROIC) | 1,0 % | 2,3 % | 1,3 % | 3,0 % | 1,6 % |
| Free-Cashflow-Rendite | −2.843,9 % | 640,5 % | −212,6 % | 817,9 % | −1.210,3 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | −1,9 % | +2,2 % | +9,6 % | +1,3 % | +0,5 % |
| Bruttogewinn | −5,9 % | +14,4 % | −0,1 % | −4,4 % | −2,2 % |
| Operatives Ergebnis | −62,3 % | +29,7 % | −46,3 % | +191,8 % | −34,8 % |
| Nettogewinn | −37,7 % | −474,6 % | +79,9 % | +43,3 % | +32,8 % |
| Gewinn je Aktie | −36,1 % | −471,6 % | +80,1 % | +43,6 % | +33,2 % |
| Freier Cashflow | −289,3 % | +232,4 % | −140,4 % | +162,6 % | −259,5 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 1Kaufen
- 6Halten
- 3Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2027 | |
|---|---|
| Umsatz (Ø) | 24,07 Mrd. |
| Umsatz (Tief – Hoch) | 24,07 Mrd. – 24,07 Mrd. |
| Gewinn je Aktie (Ø) | -2,82 |
| Gewinn je Aktie (Tief – Hoch) | -2,82 – -2,82 |
| Analysten | 1 |
Letzte Änderungen
- Deutsche Bank27. Apr. 2023Sell
- Deutsche Bank26. Apr. 2023Sell
- Deutsche Bank3. Okt. 2022Sell
- Deutsche Bank2. Okt. 2022Sell
- Evercore ISI Group30. Sept. 2022Underperform
- Evercore ISI Group29. Sept. 2022Underperform
- Deutsche Bank3. Juni 2022Sell
- Deutsche Bank2. Juni 2022Sell
Quartalszahlen
| Dez. 2023 | Juni 2023 | Apr. 2023 | Dez. 2022 | Sept. 2022 | Juni 2022 | Apr. 2022 | Nov. 2021 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,72 | -1,50 | -0,78 | -0,15 | -0,50 | -0,70 | -0,49 | – |
| Gewinn je Aktie · Tatsächlich | -7,39 | -0,73 | -1,24 | -0,14 | -0,63 | -0,60 | -1,63 | -0,67 |
| Abweichung | −926,39 % | +51,41 % | −59,49 % | +4,34 % | −25,33 % | +14,31 % | −234,89 % | – |
| Umsatz · Tatsächlich | 5,65 Mrd. | 5,65 Mrd. | 6,09 Mrd. | 6,08 Mrd. | 5,9 Mrd. | 6,01 Mrd. | 6,07 Mrd. | 6,23 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 14. Okt. 1999 | – | 0,12 |
| 15. Juli 1999 | – | 0,12 |
| 15. Apr. 1999 | – | 0,12 |
| 15. Jan. 1999 | – | 0,12 |
| 15. Okt. 1998 | – | 0,11 |
| 16. Juli 1998 | – | 0,11 |
| 16. Apr. 1998 | – | 0,11 |
| 15. Jan. 1998 | – | 0,22 |
| 16. Okt. 1997 | – | 0,20 |
| 17. Juli 1997 | – | 0,20 |
| 17. Apr. 1997 | – | 0,20 |
| 15. Jan. 1997 | – | 0,20 |
Aktiensplits
- 22. Apr. 20191:20
- 3. Feb. 19982:1
- 8. Juli 19912:1
- 30. Jan. 19842:1
- 1. Feb. 19833:2
- 2. Feb. 19814:3
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Rite Aid Corporation, operating through its various subsidiary entities, manages an extensive chain of retail pharmacies throughout the United States. The company's operations are divided into two main divisions: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment is primarily involved in dispensing both generic and branded prescription medications. In addition to pharmaceutical sales, it offers a wide assortment of health, beauty, and general convenience products. This range includes over-the-counter remedies, personal care items, cosmetics, seasonal merchandise, household goods, food and beverages, greeting cards, and pet supplies. The segment also develops and sells its own private label products. Furthermore, this division oversees its network of retail pharmacies and clinics, providing a variety of healthcare services. These services include administering immunizations for illnesses such as COVID-19, influenza, and shingles, as well as offering support to customers managing chronic conditions like high blood pressure, cholesterol, and diabetes. Counseling for weight management and tobacco cessation is also available, alongside educational guidance on medication usage and potential adverse effects. The Pharmacy Services segment is dedicated to providing an integrated suite of pharmacy benefit management (PBM) solutions. These services cover technology platforms, mail-order prescription delivery, specialty pharmacy support, the administration of pharmacy networks and rebates, claims processing, and prescription discount programs. This segment also facilitates drug benefits under the federal Medicare Part D program and offers insurance plans to individuals and groups. Its client base comprises health insurance providers, commercial employers, labor organizations, and various state and local government agencies. Beyond its brick-and-mortar locations, Rite Aid also makes its products available through its online retail website. Established in 1962, Rite Aid Corporation is headquartered in Philadelphia, Pennsylvania. However, as of October 15, 2023, the company and its affiliated businesses initiated voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code, filing their petition with the U.S. Bankruptcy Court for the District of New Jersey.
Führung
- Matthew C. SchroederChief Financial Officer & Executive Vice President
- Christopher DuPaulExecutive Vice President
- Jessica KazmaierExecutive Vice President, Chief Human Resources Officer & Chief of Staff to the Chief Executive Officer
- Thomas J. Sabatino Jr.Executive Vice President & Chief Legal Officer
- Angele Robinson-GaylordSenior Vice President of Store Development
- Christin BassettActing General Counsel & Corporate Secretary
- CEO
- Jeffrey Scott Stein
- Mitarbeitende
- 47.000
- Hauptsitz
- Philadelphia, PA, US
- Sektor
- Healthcare
- Branche
- Medical - Pharmaceuticals
- Börsengang
- 17. März 1980
- Website
- riteaid.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.